Disc Medicine Inc has 9 Schedule 13D or 13G filings on record since 2025-08-07. 3 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Fmr LLC | 12.8% | 4,875,473 | SCHEDULE 13G/A, 2026-08-06 | 2026-06-30 |
| Ai Dmi LLC | 8% | 3,018,460 | SCHEDULE 13D/A, 2025-10-22 | 2025-10-20 |
| RA Capital Management, L.P. | 5.9% | 2,228,924 | SCHEDULE 13G, 2026-01-07 | 2025-12-30 |
| Wellington Management Group LLP | 4.1% | 1,432,090 | SCHEDULE 13G/A, 2025-08-12 | 2025-06-30 |
| Frazier Life Sciences Public Fund, L.P. | 3% | 1,026,489 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| Atlas Venture Fund X, L.P. | 2.2% | 813,167 | SCHEDULE 13D/A, 2025-12-17 | 2025-12-12 |
Purpose of Transaction (Item 4)
Ai Dmi LLC
The disclosure in Item 4 to the Schedule is hereby supplemented by adding the following at the end thereof: On October 20, 2025, the Issuer entered into an underwriting agreement (the "Underwriting Agreement") with AI DMI LLC as a selling stockholder and Jefferies LLC, Leerink Partners LLC, Morgan Stanley & Co. LLC and Cantor Fitzgerald & Co. (the "Representatives"), as representatives of the several underwriters listed on Schedule I thereto (the "Underwriters"), related to an underwritten offering (the "Offering"), pursuant to which (i) the Issuer issued and sold (a) 2,619,049 shares of Common Stock at a price to the public of $84.00 per share and (b) in lieu of Common Stock to certain investors, pre-funded warrants to purchase an aggregate of 59,523 Pre-Funded Warrants at a price to the public of $83.9999 per Pre-Funded Warrant, which represents the per share public offering price for the Common Stock less the $0.0001 per share exercise price for each such Pre-Funded Warrant and (ii) AI DMI agreed to sell to the Underwriters 297,619 shares of Common Stock at a price to the public of $84.00 per share (the "Secondary Offering"). In addition, AI DMI granted the Underwriters an option exercisable for 30 days from the date of the Underwriting Agreement to purchase, at the public offering price less any underwriting discounts and commissions, up to an additional 446,428 shares of Common Stock, which the Underwriters exercised in full on October 21, 2025. AI DMI received net …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-10-22; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-07 | Fmr LLC | 12.2% | SCHEDULE 13G/A |
| 2025-08-12 | Wellington Management Group LLP | 4.1% | SCHEDULE 13G/A |
| 2025-08-14 | Frazier Life Sciences Public Fund, L.P. | 3% | SCHEDULE 13G/A |
| 2025-08-15 | Atlas Venture Fund X, L.P. | 3.1% | SCHEDULE 13D/A |
| 2025-10-22 | Ai Dmi LLC | 8% | SCHEDULE 13D/A |
| 2025-11-05 | Fmr LLC | 14.1% | SCHEDULE 13G/A |
| 2025-12-17 | Atlas Venture Fund X, L.P. | 2.2% | SCHEDULE 13D/A |
| 2026-01-07 | RA Capital Management, L.P. | 5.9% | SCHEDULE 13G |
| 2026-08-06 | Fmr LLC | 12.8% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Disc Medicine Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.